BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 7497593)

  • 21. Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.
    Meijer C; de Vries EG; Dam WA; Wilkinson MH; Hollema H; Hoekstra HJ; Mulder NH
    Br J Cancer; 1997; 76(3):290-8. PubMed ID: 9252194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
    Yamada K; Kato N; Takagi A; Koi M; Hemmi H
    Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
    Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
    Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
    Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
    Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
    Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
    Hospers GA; de Vries EG; Mulder NH
    Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
    Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
    Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
    Leone R; Fracasso ME; Soresi E; Cimino G; Tedeschi M; Castoldi D; Monzani V; Colombi L; Usari T; Bernareggi A
    Cancer Chemother Pharmacol; 1992; 29(5):385-90. PubMed ID: 1312907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A topographic study on the distribution of cisplatin in xenografted tumors on nude mice.
    Johnsson A; Cavallin-Stahl E
    Anticancer Drugs; 1996 Jan; 7(1):70-7. PubMed ID: 8742101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.
    Los G; Blommaert fA; Barton R; Heath DD; den Engelse L; Hanchett C; Vicario D; Weisman R; Robbins KT; Howell SB
    Cancer Chemother Pharmacol; 1995; 37(1-2):150-4. PubMed ID: 7497585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The formation and persistence of carboplatin-DNA adducts in rats.
    Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
    Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacokinetics of new cisplatin analogues in experimental animals].
    Fujita H; Okamoto M; Takao A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1366-72. PubMed ID: 2658824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
    Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of dextran derivatives immobilizing platinum complex (II).
    Ichinose K; Tomiyama N; Nakashima M; Ohya Y; Ichikawa M; Ouchi T; Kanematsu T
    Anticancer Drugs; 2000 Jan; 11(1):33-8. PubMed ID: 10757561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer.
    Lagrange JL; Bondiau PY; Tessier E; Chauvel P; Renée N; Etienne MC; Milano G
    Int J Cancer; 1996 Nov; 68(4):452-6. PubMed ID: 8945615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.
    Serpeloni JM; Batista BL; Angeli JP; Barcelos GR; Bianchi Mde L; Barbosa F; Antunes LM
    J Toxicol Environ Health A; 2013; 76(6):345-53. PubMed ID: 23557233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
    Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.